(Q33265642)

English

Modifications increasing the efficacy of recombinant vaccines; marked increase in antibody titers with moderately repetitive variants of a therapeutic allergy vaccine

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Modifications increasing the efficacy of recombinant vaccines; marked increase in antibody titers with moderately repetitive variants of a therapeutic allergy vaccine (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

1 reference

based on heuristic

inferred from title

author name string

Jeannette Johansson

1

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Lars Hellman

2

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

language of work or name

0 references

publication date

13 November 2006

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

1676-1682

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Identification of adjuvants that enhance the therapeutic antibody response to host IgE.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Generation of therapeutic antibody responses against IgE through vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Generation of therapeutic antibody responses against IgE in dogs, an animal species with exceptionally high plasma IgE levels

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Triggering TLR signaling in vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Use of CpG oligodeoxynucleotides as immune adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Virus-like particles as a modular system for novel vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Profound reduction in allergen sensitivity following treatment with a novel allergy vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Evidence for an early appearance of modern post-switch isotypes in mammalian evolution; cloning of IgE, IgG and IgA from the marsupial Monodelphis domestica

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Characterization and molecular cloning of the mRNA for the heavy (epsilon) chain of rat immunoglobulin E.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Properties of the extracellular calcium binding module of the proteoglycan testican

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Nidogen-2: a new basement membrane protein with diverse binding properties

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Cloning of IgE from the echidna (Tachyglossus aculeatus) and a comparative analysis of epsilon chains from all three extant mammalian lineages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

A vaccine that prevents pregnancy in women

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

HER-2 DNA and protein vaccines containing potent Th cell epitopes induce distinct protective and therapeutic antitumor responses in HER-2 transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Therapeutic antibodies elicited by immunization against TNF-alpha

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

TNF autovaccination induces self anti-TNF antibodies and inhibits metastasis in a murine melanoma model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Active vaccination against IL-5 bypasses immunological tolerance and ameliorates experimental asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Phase I study of TNFα AutoVaccIne in Patients with metastatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

The fate of self-reactive B cells depends primarily on the degree of antigen receptor engagement and availability of T cell help.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Cellular and genetic mechanisms of self tolerance and autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Aluminium compounds for use in vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Genetic engineering of recombinant hypoallergenic oligomers of the major birch pollen allergen, Bet v 1: candidates for specific immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Vaccination with genetically engineered allergens prevents progression of allergic disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Vaccine engineering improved by hybrid technology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Identifiers

10.1016/J.VACCINE.2006.10.055

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33265642&oldid=1576815571"